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Resum. La proporció de població mundial més gran de seixan­
ta anys doblarà l’actual l’any 2050. Això implicarà un augment 
de la prevalença de les malalties cròniques, que són de les més 
costoses, i que constitueixen una creixent pressió sobre els sis­
temes de salut. En aquests temps de restriccions pressupostàri­
es, l’envelliment de la població condueix a la necessitat d’un 
canvi en l’assistència sanitària. Cal un enfocament triple basat 
en el disseny de programes que millorin l’experiència del paci­
ent, així com la salut de la població, alhora que en redueixin els 
costos. El desenvolupament de la biologia molecular ha revelat 
els mecanismes subjacents de moltes malalties, i ens ha condu­
ït cap a la medicina personalitzada. A mesura que la porta a 
l’atenció predictiva i preventiva s’obre, els problemes d’accés, 
lliurament i assequibilitat a l’atenció sanitària també s’alteraran: 
del tractament de les malalties a la preservació del benestar; 
d’un sistema reactiu, orientat a la malaltia, a un sistema de salut 
predictiu, personalitzat i preventiu. 
Paraules clau: medicina personalitzada ∙ envelliment de la 
població ∙ sistemes de salut ∙ innovacions disruptives ∙ centres 
d’innovació terapèutica (CTI)
Summary. The proportion of the world’s population over the 
age of 60 will more than double by 2050. By extension, this 
means an increase in the prevalence of chronic diseases, 
which are among the costliest and constitute a growing pres­
sure on healthcare systems. In this time of budget constraints, 
aging populations drive the need for change in healthcare. A 
triple­pronged approach is needed consisting of the design of 
programs that improve the patient experience as well as the 
health of the population while lowering the costs. The develop­
ment of molecular biology has revealed the mechanisms un­
derlying many diseases, in turn leading us towards personal­
ised medicine. As the door to predictive and preventive care 
opens, the problems of access, delivery and affordability of 
healthcare will be correspondingly altered: from treating sick­
ness to preserving wellness; from a reactive, disease­oriented 
healthcare system to a personalised, predictive, and preventive 
one.  
Keywords: personalised medicine ∙ aging population ∙ 
healthcare systems ∙ disruptive innovations ∙ centres for 
therapeutic innovation (CTI)
Around the world, life spans are increasing and populations 
are aging. The proportion of the world’s population over the 
age of 60 will more than double by 2050, to more than 1 bil­
lion people—or 37% of the active population (Fig. 1). By ex­
tension, this means an increase in the prevalence of chronic 
diseases, such as cardiac and pulmonary diseases, stroke, 
cancer, diabetes, and dementia, which are among the costli­
est and constitute a growing pressure on healthcare systems. 
We are heading towards a situation in which 10 % of the pop­
ulation accounts for > 70 % of the healthcare costs (Fig. 2). 
How are we going to maintain the quality and type of health­
care systems that in the past effectively met the demands of 
the respective populations, when healthcare costs have regu­
larly outpaced the gross domestic product (GDP) for around 
the last 30 years in a row? Healthcare currently accounts for 
approximately 10 % of GDP spending in most member coun­
tries of the OECD. In the United States, it is about 17 %. 
There is a definite and imperative need for change. Since the 
global financial crisis hit in late 2008, the situation has become 
particularly dramatic. The crisis has taken a severe toll on the 
system’s input (funding from the government, companies, and 
taxpayers) and placed output (innovation in business, quality of 
healthcare delivery) under intense strain, raising questions as to 
how we shall pay healthcare costs in the future. In this time of 
budget constraints, aging populations drive the need for 
change in healthcare. This is a challenge that also opens up a 
wealth of opportunities for innovative approaches to the shift in 
healthcare delivery. For the elderly, for example, we must move 
from reactive care, which is typically hospital­based, to proac­
tive care, at home and integrated with social care. 
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To do so requires the following:
•   Innovative ways to achieve compliance
•   Early diagnosis
•   Integrated  care  models  for  chronic  diseases  (remote 
monitoring)
•   Increase uptake of technology-based solutions for  inde­
pendent living
•   Corresponding integration of these concepts in the plan­
ning of buildings, cities, and environments
Active and healthy aging is a priority in Europe, as addressed 
by the program ‘European Innovation Partnership (EIP) in Ac­
tive and Healthy Aging,’ which seeks to integrate projects ad­
dressing this issue from social, clinical, technological, and eco­
nomic points of view. 
There are many different perspectives regarding how health­
care can become more sustainable. According to Harvard 
Business School professor Clayton Christensen, in his book 
The Innovator’s Prescription, healthcare management is an is­
sue in which ‘disruptive innovation’ is needed to change the 
way healthcare is accessed, delivered, and paid for; to provide 
treatment for unmet clinical needs; and to bend the cost curve 
for healthcare. Innovation should provide not only improve­
ments in care but also value, defined according to patient out­
comes and the impact on healthcare system resources. ‘Dis­
ruptive innovations’ could come in the form of new technological 
enablers that simplify processes, or as new business models, 
or in the form of economically coherent value networks, all of 
which redesign the way we treat patients. 
Wireless sensors and devices, genomics, social networking, 
mobile connectivity and bandwidth, imaging, health informa­
tion systems, the Internet, and big data are the top technologi­
cal trends in the digital revolution that are transforming health­
care (Fig. 2). There is a convergence of the potential of all these 
technologies and over time their level of development will make 
them more affordable. For example, in the space of 10 years, 
the cost of sequencing a genome has gone from more than 10 
million USD to less than 1000 USD. 
Billions of data points per individual are being generated 
with these new technologies. The great challenge of medicine 
in the 21st century is complexity: How do we extract useful 
information from these data? How do we make correlations? 
How do we interpret the data? Medicine is increasingly be­
coming an informational science: through systems and holistic 
approaches we will be able to understand wellness and dis­
ease, by attacking complexity efficiently; emerging technolo­
gies will allow us to explore new dimensions of the patient 
‘data space’; and with the aid of transforming analytic tools we 
will be able to decipher the billions of data points for the indi­
vidual, by acquiring, storing, transmitting, integrating, mining, 
and creating predictive models. 
Personalised medicine 
The development of molecular biology has revealed the mecha­
nisms underlying many diseases, in turn leading us towards per­
sonalised medicine. As the door to predictive and preventive 
care opens, the problems of access, delivery and affordability 
Fig. 1. Population aged 60 and over: world and development re­
gions, 1950–2050. Source: Department of Economic and Social Af­
fairs, United Nations.
Fig. 2. Imperative for 
change: the few cost the 
most.
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will be correspondingly altered: from treating sickness to pre­
serving wellness; from a reactive, disease­oriented healthcare 
system to a personalised, predictive, and preventive one. 
The digitalization of biology and medicine is transforming the 
way we treat patients in what is now called P4 Medicine: predic-
tive, because from the available information we can predict the 
phenotype or the pathology of a patient’s disease; personalised, 
because we can treat patients individually, according to their 
specific condition; preventive, because the emphasis will ex­
pand to include disease prevention; and participatory, because 
it enables patients to be an active part of their own healthcare. 
Since 2003, coinciding with the Human Genome Project, 
we have progressed from understanding the structure of ge­
nomes to understanding the biology of genomes and subse­
quently the biology of disease. This new knowledge is the key 
to advancing the science of medicine and to improving the ef­
fectiveness of healthcare. The goal of personalised medicine is 
to be able to distinguish between patients who, while they may 
have the same symptoms, differ in the pathways underlying 
their disease. Moreover, we know that patients react very dif­
ferently to therapeutics, reflected in differences in the percent­
age response to therapy. With personalised medicine, non­re­
sponders can be identified prior to treatment, thus sparing 
these patients unnecessary discomfort and the healthcare sys­
tem unnecessary costs.
Let us take lymphoma as an example. Only 100 years ago, 
lymphoma was described as a disease of the blood. But thanks 
to molecular biology we have been able to discriminate be­
tween lymphoma and leukaemia (80 years ago) and between 
different types of lymphomas and leukaemia according to the 
dysfunctional mechanisms—from a total of five types 60 years 
ago to the 38 types of leukaemia and 51 types of lymphoma 
recognised today. But of course, all these studies take time and 
need to be conducted through huge consortiums based on col­
laborations between researchers from different fields. Here in 
Catalonia, these research groups include that of Professor Elías 
Campo. Dr. Campo’s laboratory is financed by the NIH and is 
leading a huge effort in the study of chronic lymphatic leukaemia 
(CLL). This group recently published a report on the types of 
cells that give rise to CLL and the elements that cause certain 
cells to develop this pathology. Another group is that of Profes­
sor Roderic Guigó, co­head researcher of the ENCODE project 
and a leader in bioinformatics who works at the Centre for Ge­
nomic Regulation. An example of the new business models is 
Inbiomotion, a spin­off of the Institute of Biomedical Research 
(IRB) and the Catalan Institution for Research and Advanced 
Studies (ICREA). Headed by Professor Roger Gomis, the com­
pany has just obtained venture capital to fund the development 
of an assay for use in validating the capacity of a biomarker to 
predict bone metastases in cancer patients. 
Redefining business models
The rules under which the healthcare industry has operated 
since its inception have changed completely because of glo­
bal economic trends, policy revisions, marketplace demands, 
and technological breakthroughs. Consequently, companies 
have been compelled to devise new strategies to ensure their 
continued success. 
Biopharmaceutical companies are under pressure to reduce 
expenditures, as drug development costs increase, patents ex­
pire, competition from generics increases, regulations become 
stiffer, and pipelines dry up. The pressure is causing these com­
panies to redefine completely their approach to innovation, in 
turn realigning the roles of the different stakeholders, such as 
academia, venture capitalists, and biotech. Faster and cheaper 
ways to bring new drugs to the market are needed. The era of 
blockbusters such as Pfizer’s Lipitor is over. As the annual sales 
trends of traditional pharmaceuticals decrease and the sales of 
bio­therapeutics increase, the pharmaceutical industry is shift­
ing from medium efficiency/overall­patient medicines to an in­
creasing focus on high efficiency/patient­targeted and person­
alised therapies. As such there is a move away from internal 
R&D to approaching external resources for new ideas, e.g., 
through greater reliance on partnerships with biotech and 
academia as sources of innovation. Pharmaceutical companies 
are no longer able to generate and access all the information 
underlying the different pathologies they consider to be of inter­
est. Instead, they are financing collaborations with different re­
search groups and universities but also with smaller companies 
to be able to more efficiently access innovation. For example, 
Pfizer has established a CTI (Center for Therapeutic Innovation) 
at the University of California­San Francisco and another at New 
York University. The company has invested US$50M over 5 
years to finance an open network of researchers from universi­
ties, hospitals, and Pfizer itself to identify and advance promis­
ing experimental drugs to proof­of­concept stage. This strategy 
is expected to accelerate pre­clinical development. 
Similar approaches have been initiated by the other major 
pharmaceutical companies to achieve the same goal: bringing 
new technologies to the patient. Johnson and Johnson, for in­
stance, has launched a new incubator, Janssen Labs, in San 
Diego, California, which finances research that comes out of 
public laboratories, typically in the form of small biotech com­
panies. This is more efficient in terms of access to basic re­
search, in particular the elucidation molecular pathways. In ad­
dition, the industry is increasingly turning to other strategies, 
including the use of virtual models, the variabilization of fixed 
costs, and outsourcing non­critical steps in drug development. 
Strong project management, research and clinical oversight, 
and the taxpayers’ involvement are critical in the new ecosys­
tem. Pharmaceutical companies must also work on a more eq­
uitable level with diagnostic companies, e.g., by involving them 
at earlier stages of drug development, as companion diagnos­
tics become more common. Diagnostics accounted for less 
than 2 % of healthcare spending but affected more than 60 % 
of critical decision­making. Interest in these measures is also 
being shown by large research institutes. Francis Collins, the 
director of the NIH, has launched the National Center for Ad­
vancing Translational Sciences (NCATS) to develop innovative 
ways to reduce, remove, or bypass the many time­consuming, 
costly bottlenecks in the translational pipeline. Again, the goal 
is to shorten the path to clinical phases.
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Genomic medicine, education, and society
The imperatives for genomic medicine are:
•   Making genomics-based diagnostic routine 
•   Defining the genetic components of disease 
•   Comprehensive characterization of cancer genomes
•   Implementing practical systems for clinical genomics  in­
formatics
•   Understanding the role of the human microbiome in health 
and disease
 
Certainly we have to move from healthcare based on data 
collection to a system that is more proactive, in which the data 
are integrated. Bioinformatics and computational biology are 
the tools that allow us to analyse, integrate, and visualize the 
data. Moreover, training and education are essential. Clini­
cians are not trained to deal with all the genomic information 
that is available, nor do they possess the skills needed to cope 
with the possible social, communication, legal, and ethical im­
pacts of this information. In the coming years, primary and 
secondary education must incorporate this type of training, 
equipping students with general information about the ge­
nome, its ethical use, and the concepts of risk and probability. 
Public outreach is crucial to truly sensitise the population 
about the opportunities but also the risks involved with the ad­
vancement of these new technologies. It is also important to 
train and build the genomic competences of genomic provid­
ers, clinicians, nurses, etc. And of course, the next generation 
of genomic researchers must be trained in statistics, compu­
ter science, and other, related fields that are currently not part 
of the biological and medical science curricula. 
Similarly, with regard to genomics and society there are 
many ethical, psychosocial, legal, and public policy issues that 
need to be dealt with. The ability to identify an individual’s ge­
netic background and the possible outcomes of it could signifi­
cantly influence the behaviour of that person, the many implica­
tions of which must be taken into account.  
Drivers. There are many drivers in the healthcare system. The 
main ones are: (i) patients, who want safer and more effective 
drugs but also a more active role in the own healthcare; (ii) pay­
ers, who need to be certain that the money spent generates 
significant medical benefit for the patient; (iii) regulators, whose 
approval of a drug is based on its safety and efficacy; and (iv) 
industry, which by reducing development time and costs can 
increase its success and thus their success rate.
Barriers. Of course, there are also barriers that hinder the full 
integration of personalised medicine into medical practice. 
These include: (i) scientific and technical barriers, such as data 
management, storage and analysis; (ii) regulators, whose 
knowledge does not evolve at the same pace as scientific and 
technical progress demand; (iii) reimbursement processes, as 
clear guidelines specifying reimbursement for services provided 
are lacking, including the assurance to molecular diagnostic 
companies that they will be paid for the value they contribute; 
(iv) physicians, who are challenged by structural barriers in 
which incentives are not aligned to prioritize prevention versus 
treatment and who are thus not trained accordingly; and (v) 
pharmaceutical and diagnostic companies, who must recog­
nize the need to work together to provide value to the system. 
A more holistic strategy is needed, such as the top down 
approaches used in some countries to implement genomics 
in healthcare. In the United Kingdom, for example, a joint 
strategy for the National Health Service (NHS) was recently 
commissioned with the aim of incorporating genomics into 
the healthcare system. Thus, the Human Genomics Strategy 
Group (HGSG) is responsible for monitoring advances in ge­
netics and genomics research, both basic and translational, 
to evaluate their benefit to the healthcare services within the 
NHS: translating research into quality­assured care path­
ways; developing a service delivery infrastructure (from com­
missioning initial tests to counselling patients and their fami­
lies); providing a bioinformatics platform to store and manage 
data; training the NHS workforce; addressing the legal and 
ethical issues; and raising public awareness. 
Challenges ahead
A triple­pronged approach is needed consisting of the design 
of programs that improve the patient experience as well as the 
health of the population while lowering the costs. This is likely 
to best be accomplished by moving from a data­collecting 
healthcare system to one that is data­driven. We must devel­
op both medium­ and long­term strategies (at the policy and 
clinical levels). Performance must be monitored by linking 
technology to health outcomes. There needs to be a realign­
ment of incentives such that waste is punished and quality and 
results rewarded. Other issues to be addressed include those 
dealing with reimbursement and the need to better promote 
the role of health technology assessment in verifying that in­
novations introduced into the system bring value to it and jus­
tify the additional cost. The technological revolution is limited 
by economic, organisational, and technological disparities 
among countries, and the capacity of these countries to over­
come them must be taken into account. But there will also be 
a new range of competences, in the form of systematic think­
ing, project management, communication, clinical genomics 
and IT. These will involve everyone who participates in the 
healthcare system, from clinicians to patients.
If we really want to have a continuously adapting health­
care system, one that is able to incorporate innovation and 
assessment, we must begin by being efficient, specifically at 
the level that connects care, research, and evidence, and in 
building networks between clinicians, patients, researchers, 
and society at large. 
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